Login to Your Account

Serono’s Rebif Wins Approval; Biogen Gears Up For MS Fight

By Randall Osborne

Monday, March 11, 2002
The regulatory battle between two biotechnology heavyweights over multiple sclerosis treatments has ended, but the marketing war has just begun, with Serono SA gaining FDA approval of Rebif (interferon beta 1-a), which allows the firm to make an end run around competitor Biogen Inc.’s orphan drug status for Avonex (another form of interferon beta 1-a). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription